Læknablaðið

Árgangur

Læknablaðið - 15.10.2012, Blaðsíða 33

Læknablaðið - 15.10.2012, Blaðsíða 33
Y F I R L I T Heimildir 1. Jóhannesson Þ, Kristinsson J, Snædal J. Hrömunarsjúk- dómar í heila - oxavamarensím og kopar. Kynning á rannsóknum. Læknablaðið 2003; 89:659-71. 2. Torsdottir G, Kristinsson J, SveinbjömsdotHr S, Snaedal J, Johannesson T. Copper, ceruloplasmin, superoxide dismutase and iron parameters in Parkinson's disease. Pharmacol Toxicol 1999; 85:239-43. 3. Torsdottir G, Sveinbjömsdottir S, Kristinsson J, Snaedal J, Johannesson T. Ceruloplasmin and superoxide dismutase (SODl) in Parkinson's disease: A follow-up study. J Neurol Sci 2006; 241: 53-8. 4. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir A, Baldvinsson M, Johannesson T. Copper, cemloplasmin and superoxide dismutase in patients with Alzheimer's disease. A case-control study. Dement Geriatr Cogn Disord 1998; 9: 239-42. (Cp-sérvirkni í þessari rannsókn, sem nefnd er í meginmáli, var fyrst reiknuð út síðar.) 5. Torsdottir G, Kristinsson J, Snaedal J, Johannesson T. Cemloplasmin and iron proteins in the semm of patients with Alzheimer's disease. Dement Geriatr Cogn Disord Extra 2011; 1:366-71. 6. Holmberg CG, Laurell CB. Investigations in semm copper I. Nature of semm copper and its relation to the iron- binding protein in human semm. Acta Chem Scand 1947; 1:944-50. 7. Harris ZL, Morita H, Gitlin JD. The biology of human cemloplasmin. In: Messerschmidt A, ed. Multi-Copper Oxidases (chapter 10). World Scientific, Singapore 1997: 285-305. 8. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillivray RTA, Gitlin JD. Acemloplasminemia: Molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci 1995; 22: 2539-43. 9. Vassiliev V, Harris ZL, Zatta P. Cemloplasmin in neurodegenerative diseases. Brain Res Rev 2005; 49: 633- 40. 10. Texel SJ, Xu X, Harris ZL. Cemloplasmin in neurodegenerative diseases. Biochem Soc Trans 2008; 36: 1277-81. 11. Barber EF, Cousins RJ. Interleukin-l-stimulated induction of cemloplasmin synthesis in normal and copper-deficient rats. J Nutr 1988; 118:375-81. 12. Barber EF, Cousins RJ. Induction of cemloplasmin synthesis by retinoic acid in rats: Influence of dietary copper and vitamin A status. J Nutr 1987; 117:1615-22. 13. Roberts EA, Sarkar B. Liver as a key organ in the supply, storage, and excretion of copper. Am J Clin Nutr 2008; 88 ( suppl): 851S-854S. 14. Torsdottir G, Gudmundsson G, Kristinsson J, Snaedal J, Johannesson T. Cemloplasmin and superoxide dismutase (SODl) in heterozygotes for Wilson disease: A case control study. Neuropsychiatr Dis Treat 2009; 5:55-9. 15. Patel BN, David S. A novel glycosylphosphatidylinositol- anchored form of ceruloplasmin is expressed by mammalian astrocytes. J Biol Chem 1997; 272: 20185-90. 16. Hellman NE, Gitlin JD. Cemloplasmin metabolism and function. Ann Rev Nutr 2002; 22:439-58. 17. Harris ZL, Klomp LW, Gitlin JD. Aceruloplasminemia: an inherited neurodegenerative disease with impairment of iron homeostasis. Am J Clin Nutr 1998; 67 (Suppl): 972S-977S. 18. Harris ZL, Durley AP, Man TK, Gitlin JD. Targeted gene dismption reveals an essential role for cemloplasmin in cellular iron efflux. Proc Natl Acad Sci 1999; 96:10812-7. 19. Jeong SY, David S. Glycosylphosphatidylinositol- anchored cemloplasmin is required for iron efflux from cells in the central nervous system. J Biol Chem 2003; 278: 27144-8. 20. De Domenico I, Ward DM, di Patti MCB, Jeong SY, David S, Musci G, Kaplan J. Ferroxidase activity is required for the stability of cell surface ferroportin in cells expressing GPI-cemloplasmin. EMBO J 2007; 26:2823-31. 21. Zecca L, Youdim MB, Riederer P, Connor JR, Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004; 5: 863-73. 22. Altamura S, Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimer's Dis 2009; 16:879-95. 23. Bamham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Dmg Discov 2004; 3:205-14. 24. Amal N, Cristalli IX), de Alaniz MJT, Marra CA. Clinical utility of copper, cemloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res 2010; 1319:118-30. 25. Bhamcha KJ, Friedman JK, Vincent AS, Ross ED. Lower semm cemloplasmin levels correlate with younger age of onset in Parkinson's disease. J Neurol 2008; 255:1957-62. 26. Jin L, Wang J, Zhao L, Jin H, Fei G, Zhang Y, et al. Decreased semm cemloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease. Brain 2011; 134: 50-8. 27. Martinez-Hemandez R, Montes S, Higuera-Calleja J, Yescas P, Boll MC, Diaz-Ruiz A, et al. Plasma cemloplasmin ferroxidase activity correlates with the nigral sonographic area in Parkinson's disease patients: A pilot study. Neurochem Res 2011; 36: 2111-5. 28. Berg D, Hochstrasser H, Schweitzer KJ, Riess O. Disturbance of iron metabolism in Parkinson's disease - ultrasonography as a biomarker. Neurotox Res 2006; 9: 1-13. 29. Hochstrasser H, Bauer P, Walter U, Behnke S, Spiegel J, Csoti I, et al. Cemloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease. Neurology 2004; 63:1912-7. 30. Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, et al. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J Neurochem 2008; 106:1866-75. 31. Uversky VN. Neurotoxicant-induced animal models of Parkinson's disease: understanding the role of rotenone, maneb and paraquat in neurodegeneration. Cell Tissue Res 2004; 318:225-41. 32. Inden M, Kitamura Y, Abe M, Tamaki A, Takata K, Taniguchi T. Parkinsonian rotenone mouse model: Reevaluation of long-term administration of rotenone in C57BL/6 mice. Biol Pharm Bull 2011; 34:92-6. 33. Hineno A, Kaneko K, Yoshida K, Ikeda S. Ceruloplasmin protects against rotenone-induced oxidative stress and neurotoxicity. Neurochem Res 2011; 36:2127-35. 34. Blennow K. Alzheimers sykdom - patofysiologi. Information frán Lakemedelsverket 2002; 7/8: 21-34. 35. Connor JR, Menzies SL, St Martin SM, Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 1992; 31: 75-83. 36. Connor JR, Snyder BS, Beard JL, Fine RE, Mufson EJ. Regional distribution of iron and iron-regulatory proteins in the brain in aging and Alzheimer's disease. J Neurosci Res 1992; 31:327-35. 37. Smith MA, Harris PLK, Sayre LM, Perry G. Iron accumulation in Alzheimer disease is a source of redox- generated free radicals. Proc Natl Acad Sci 1997; 94: 9866- 8. 38. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW, Cohen ML, et al. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. J Alzheimers Dis 2010; 19: 363-72. 39. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, et al. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001; 60: 759-67. 40. Torsdottir G, Kristinsson J, Snaedal J, Sveinbjömsdottir S, Gudmundsson G, Hreidarsson S, et al. Case-control studies on ceruloplasmin and superoxide dismutase (SODl) in neurodegenerative diseases: A short review. J Neurol Sci 2010; 299:51-4. 41. Brewer GJ, Kanzer SH, Zimmerman EA, Celmins DF, Heckman SM, Dick R. Copper and ceruloplasmin abnormalities in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2010; 25:490-7. 42. Bucossi S, Ventriglia M, Panetta V, Salustri C, Pasqualetti P, Mariani S, et al. Copper in Alzheimer's disease: A meta- analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis 2011; 24:175-85. 43. Squitti R, Ghidoni R, Scrascia F, Benussi L, Panetta V, Pasqualetti P, et al. Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimers Dis 2011; 23: 239-48. 44. Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM. Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol 2011; 94:296-306. 45. Choi BS, Zheng W. Copper transport to the brain by the blood-brain barrier and blood-CSF barrier. Brain Res 2009; 1248:14-21. 46. Logroscino G, Marder K, Graziano J, Freyer G, Slavkovich V, Lolacono N, et al. Altered systemic iron metabolism in Parkinson's disease. Neurology 1997; 49: 714-7. 47. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, et al. Common variants at ABCA7, MS4A6A/ MS4A4E, EPHAl, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet 2011; 43: 429-36. 48. Sveinbjömsdottir S, Hicks AA, Jonsson T, Petursson H, Gudmundsson G, Frigge, et al. Familial aggregation of Parkinson's disease in Iceland. N Engl J Med 2000; 343: 1765-70. 49. Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, et al. Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 2008; 321:1218- 21. LÆKNAblaðið 2012/98 537
Blaðsíða 1
Blaðsíða 2
Blaðsíða 3
Blaðsíða 4
Blaðsíða 5
Blaðsíða 6
Blaðsíða 7
Blaðsíða 8
Blaðsíða 9
Blaðsíða 10
Blaðsíða 11
Blaðsíða 12
Blaðsíða 13
Blaðsíða 14
Blaðsíða 15
Blaðsíða 16
Blaðsíða 17
Blaðsíða 18
Blaðsíða 19
Blaðsíða 20
Blaðsíða 21
Blaðsíða 22
Blaðsíða 23
Blaðsíða 24
Blaðsíða 25
Blaðsíða 26
Blaðsíða 27
Blaðsíða 28
Blaðsíða 29
Blaðsíða 30
Blaðsíða 31
Blaðsíða 32
Blaðsíða 33
Blaðsíða 34
Blaðsíða 35
Blaðsíða 36
Blaðsíða 37
Blaðsíða 38
Blaðsíða 39
Blaðsíða 40
Blaðsíða 41
Blaðsíða 42
Blaðsíða 43
Blaðsíða 44
Blaðsíða 45
Blaðsíða 46
Blaðsíða 47
Blaðsíða 48
Blaðsíða 49
Blaðsíða 50
Blaðsíða 51
Blaðsíða 52
Blaðsíða 53
Blaðsíða 54
Blaðsíða 55
Blaðsíða 56
Blaðsíða 57
Blaðsíða 58
Blaðsíða 59
Blaðsíða 60
Blaðsíða 61
Blaðsíða 62
Blaðsíða 63
Blaðsíða 64

x

Læknablaðið

Beinir tenglar

Ef þú vilt tengja á þennan titil, vinsamlegast notaðu þessa tengla:

Tengja á þennan titil: Læknablaðið
https://timarit.is/publication/986

Tengja á þetta tölublað:

Tengja á þessa síðu:

Tengja á þessa grein:

Vinsamlegast ekki tengja beint á myndir eða PDF skjöl á Tímarit.is þar sem slíkar slóðir geta breyst án fyrirvara. Notið slóðirnar hér fyrir ofan til að tengja á vefinn.